Current NRC clients incubating in Charlottetown

Ceapro Inc.

Ceapro Inc. is a Canadian biotechnology company specializing in the identification, extraction, purification and commercialization of therapeutic bioactive compounds from natural sources. Ceapro’s primary focus is the cosmeceutical and personal care markets, and to a lesser extent, the veterinary market. Ceapro currently has six commercial ingredients—oat avenanthramides, oat beta glucan, oat oil, superfine oat flours, oat peptides and lupin peptides. New ingredients from other plant sources will be developed in the future and serve as the basis for future growth plans.

NRC collaborators are working with Ceapro by providing expertise in the areas of in vivo and ex vivo assays, defining mechanisms of action, and characterizing possible therapeutic effects of Ceapro’s bioactive ingredients. Through this collaboration, Ceapro will have access to the NRC team and its state-of-the-art facility. NRC researchers have immunology and natural products chemistry expertise, which will be invaluable to further strengthen the science behind Ceapro’s existing products, to screen new bioactive molecules and to develop and commercialize future ingredients.

Contact

David Fielder, Chief Scientific Officer
Website: www.ceapro.com


Chemaphor Inc.

Chemaphor Inc. uses its core expertise in organic chemistry to develop premium products for commercialization in the nutrisciences, pharmaceutical and cosmetic sectors. Chemaphor's goal is to fully exploit its proprietary platform of carotenoid oxidation compounds by identifying and unlocking previously unrecognized benefits of carotenoids for human and animal health benefits.

NRC collaborators are working with Chemaphor on identifying fractions responsible for bioactivity and determining the mechanism of action of the company’s carotenoid oxidation compounds. NRC researchers bring expertise in the area of in vitro assays used in determining mechanisms of action. Chemaphor also benefits from co-location within the Industry Partnership Facility, particularly though proximity to NRC’s research team and state-of-the-art equipment.

Contact

David Hankinson, Chief Executive Officer
Website: www.chemaphor.com


Nautilus Biosciences Canada Inc.

Founded in 2007, Nautilus Biosciences Canada is a marine biotechnology company focused on the discovery and development of marine-derived natural products with applications in a range of human and animal health and wellness industries. A key differentiator for Nautilus is its high value Marine Natural Products Bank (MNPB), which contains organisms from diverse geographic backgrounds with an unusually broad biodiversity of invertebrates, algae and microbes.

The company benefits from access to NRC’s technology platforms and screening capabilities. NRC researchers offer expertise in the areas of screening natural compounds for anti-inflammatory and anticancer activities.

Contact

Russell Kerr, Chief Executive Officer
Website: www.nautilusbiosci.net


Neurodyn Inc.

Neurodyn Inc. is working to develop and market products for early detection and treatment of neurological diseases including ALS (amyotrophic lateral sclerosis), Parkinson’s and Alzheimer’s disease.

The company’s patent-pending animal models offered by CNS CRO replicate the neurodegenerative process from its earliest stages. This provides an ideal test platform for preclinical evaluation of potential new diagnostics and therapeutics. Neurodyn’s Charlottetown facility is dedicated to developing this animal model into a Good Laboratory Practices-compliant commercial testing platform.

NRC collaborators are working with Neurodyn to undertake a detailed analysis of the changes in protein, lipid and small molecule metabolites during the progression of neurodegenerative disease. NRC researchers bring expertise in the areas of analytical chemistry, metabolism and neuroscience.

Contact

D. G. Kay, Chief Scientific Officer
Website: www.neurodyn.ca


OmniActive Health Technologies

OmniActive Health Technologies supplies novel dietary ingredients for the human health and wellness markets. Its current offerings include Lutemax®, a range of lutein containing products for eye health, and Capsimax™, a capsicum-containing product for weight management. OmniActive employs proprietary delivery platforms to improve functionality and ingredient bioavailability. Its Charlottetown facility is focused on the development of new dietary ingredients for use in nutraceuticals and functional foods.

OmniActive collaborates with NRC researchers to develop new dietary ingredients and to improve the company’s existing products. The collaboration recognizes the expertise of NRC scientists in performing in vitro assays, used in evaluating natural products for bioactivity and their mechanism of action. At NRC, OmniActive will also have select products tested in proof-of-concept, pre-clinical studies to support subsequent testing of novel dietary ingredients in humans. Its presence in the Industry Partnership Facility also affords OmniActive access to NRC’s state-of–the-art equipment.

Contact

Dr. Jayant Deshpande, President
Website: www.omniactives.com


Phyterra Bio Inc.

Phyterra Bio Inc. is developing new technology to better deliver vaccines and nutrients to animals. The company’s patented platform technology uses transgenic single-celled algae to produce and deliver biologically active peptides or proteins to animals. The aquaculture health and pharmaceutical products will include cost-effective oral and immersion vaccines, and antimicrobial peptides.

NRC is collaborating with Phyterra Bio’s R&D team to further develop the company’s platform for cost-effective expression of bioactive proteins and their delivery as oral health care products. The company will benefit from access to NRC’s technology platforms and expertise in the areas of analytical chemistry and molecular genetics.

Contact

Garth Greenham, Managing Director
Phyterra Bio Inc.
Telephone: 647-204-4095
Email: garthgreenham@phyterra.com


Phyterra Yeast Inc.

Phyterra Yeast Inc. is developing and commercializing advanced yeast products to reduce naturally occurring chemicals, which either affect final product quality or are classified by the WHO as probable human carcinogens. Current projects include the reduction of hydrogen sulphide, ethyl carbamate and acrylamide, which are naturally occurring by-products from food and beverage processing. These are found in many commonly consumed items such as fermented products, including alcoholic beverages as well as baked and fried foods.

NRC is collaborating with Phyterra Yeast’s R&D team to create cost-effective methodologies for the development of functional enhanced yeast products by providing expertise in the areas of analytical chemistry and molecular genetics.

Contact

Garth Greenham, Managing Director
Phyterra Bio Inc.
Telephone: 647-204-4095
Email: garthgreenham@phyterra.com

Report a problem or mistake on this page
Please select all that apply:
Privacy notice